Diagnostic and prognostic impact of osteopontin expression in endometrial cancer.
The role of osteopontin as a biomarker in endometrial cancer has not been conclusively established. We evaluated the expression and potential of osteopontin as a biomarker for endometrial cancer. Real-time polymerase chain reaction and immunohistochemistry revealed osteopontin overexpression in endometrial cancer. The plasma osteopontin level in endometrial cancer was significantly higher than in healthy controls (P< 0.001). In FIGO stage I endometrial cancer, osteopontin correctly identified 18 of 29 cases (62.1%) that were not detected by CA125. By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival (hazard ratio = 3.18, P= 0.035).
Cho
HanByoul
H
Department of Obstetrics and Gynecology, Yongdong Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Kang
Eun Suk
ES
Kim
Young Tae
YT
Kim
Jae-Hoon
JH
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000401:mortality; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D053495:Osteopontin / Q000032:analysis / Q000097:blood* / Q000235:genetics; D016133:Polymerase Chain Reaction; D011379:Prognosis; D016016:Proportional Hazards Models
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D053495:Osteopontin